Company news

Bavarian Nordic A/S news in 2026

Bavarian Nordic A/S's news releases, calls and decks from 2026, newest first.

View company

Bavarian Nordic to Supply and Donate Vaccines for Global Mpox Emergency Stockpile

October 27, 2026

- Transactions in Connection with Share Buy-Back Program

October 19, 2026

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

October 19, 2026

- Transactions in Connection with Share Buy-Back Program

October 12, 2026

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

October 12, 2026

Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance

October 8, 2026

- Transactions in Connection with Share Buy-Back Program

October 5, 2026

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

October 5, 2026

Bavarian Nordic – Notification of Holding of Treasury Shares

September 22, 2026

Tarja Stenvall Appointed Chief Executive Officer of Bavarian Nordic

September 17, 2026

Bavarian Nordic Launches First Tranche of New Share Buy-Back Program

September 1, 2026

Bavarian Nordic Reports Strong First Half 2026 Results

August 21, 2026

Bavarian Nordic to Launch New Share Buy-back Program of up to DKK 750 Million

August 21, 2026

Bavarian Nordic Upgrades its Full-Year 2026 Financial Guidance

August 21, 2026

Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years

August 7, 2026

Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

July 13, 2026

- Completion of Share Buy-Back Program

July 13, 2026

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

June 29, 2026

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

June 9, 2026

Bavarian Nordic Announces Interim Results for the First Three Months of 2026

May 13, 2026

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox Vaccines

May 11, 2026

Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S

April 21, 2026

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

April 20, 2026

Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine

April 16, 2026

- Transactions in Connection with Share Buy-Back Program

April 13, 2026

Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years

March 27, 2026

Bavarian Nordic A/S – Notice Convening Annual General Meeting

March 24, 2026

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

March 12, 2026

Bavarian Nordic Launches Next Tranche of Share Buy-Back Program

March 12, 2026

Bavarian Nordic Publishes Annual Report 2025

March 12, 2026

Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

March 11, 2026

Paul Chaplin Steps Down as CEO of Bavarian Nordic

March 2, 2026

Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada

February 18, 2026

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026

February 12, 2026

Bavarian Nordic – Completion of Share Buy-Back Program

February 9, 2026

Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil

January 23, 2026

Bavarian Nordic Launches Planned Share Buy-Back Program

January 7, 2026

Calls in 2026

Decks in 2026